The DOI matches its Crossref record; 475 of the 475 references it cites were found in a registry or an index.
Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration
Open accessAbstract
Adenosine acts in parallel as a neuromodulator and as a homeostatic modulator in the central nervous system. Its neuromodulatory role relies on a balanced activation of inhibitory A(1) receptors (A1R) and facilitatory A(2A) receptors (A2AR), mostly controlling excitatory glutamatergic synapses: A1R impose a tonic brake on excitatory transmission, whereas A2AR are selectively engaged to promote synaptic plasticity phenomena. This neuromodulatory role of adenosine is strikingly similar to the role of adenosine in the control of brain disorders; thus, A1R mostly act as a hurdle that needs to be overcame to begin neurodegeneration and, accordingly, A1R only effectively control neurodegeneration if activated in the temporal vicinity of brain insults; in contrast, the blockade of A2AR alleviates the long-term burden of brain disorders in different neurodegenerative conditions such as ischemia, epilepsy, Parkinson's or Alzheimer's disease and also seem to afford benefits in some psychiatric conditions. In spite of this qualitative agreement between neuromodulation and neuroprotection by A1R and A2AR, it is still unclear if the role of A1R and A2AR in the control of neuroprotection is mostly due to the control of glutamatergic transmission, or if it is instead due to the different homeostatic roles of these receptors related with the control of metabolism, of neuron-glia communication, of neuroinflammation, of neurogenesis or of the control of action of growth factors. In spite of this current mechanistic uncertainty, it seems evident that targeting adenosine receptors might indeed constitute a novel strategy to control the demise of different neurological and psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neurogenesis in the adult human hippocampus
Eriksson, P. S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D. A., & Gage, F. H. (1998) · Nature Medicine · doi:10.1038/3305 · Cited by 6,369
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Gage, F. H. (2000) · Science · doi:10.1126/science.287.5457.1433 · Cited by 4,786
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Receptors for Purines and Pyrimidines
Burnstock, G., & Verkhratsky, A. (2012) · Springer eBooks · doi:10.1007/978-3-642-28863-0_5 · Cited by 3,962
Flagged first, then by citations
Research works printed but not linked: 3
- Porciúncula, 2006, Blockade of adenosine A 2A receptors differently alters convulsive behaviour and prevents hippocampal damage in two models of temporal lobe epilepsy, Purinergic Signal, 2, 134
- Fernandez, 2008, .U.-C.I. Group, The safety and efficacy of istradephylline, an adenosine A2A antagonist, as monotherapy in Parkinson's disease: results of the KW-6002-US-051 trial, Mov. Disord., 23, S87
- Kaster, 2010, Genetic or pharmacological blockade of adenosine A2A receptors prevents behavioral and morphological effects of chronic stress in mice, Purinergic Signal, 6, S93
Cited by
Sorted by citations
Items 301–400 of 425
Adenosine A2A signaling in mood disorders: How far have we come?
Bevilacqua, L. M., Neto, F. D. S., & Kaster, M. P. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.08.006 · Cited by 7
Self-citationDynamic Neuro-Glial-Vascular Responses in a Mouse Model of Vascular Cognitive Impairment
Kim, K. J., Patterson, R. E., Diaz, J. R., O’Herron, P. J., Bush, W., Althammer, F., Stern, J. E., Brands, M. W., Bagi, Z. A., & Filosa, J. A. (2024) · Neuroglia · doi:10.3390/neuroglia5040032 · Cited by 6
Mihajlović, K., Adžić, M., Dragić, M., Scortichini, M., Jacobson, K. A., & Nedeljković, N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175943 · Cited by 6
ATP Metabolism as Biomarker Target for Cardiovascular Protection
Yeung, P. K. F. (2013) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000e118 · Cited by 6
de Azevedo, M. I., Silva, A. S. D., Ferreiro, L., Doleski, P. H., Tonin, A. A., Casali, É. A., Moritz, C. E. J., Schirmbeck, G. H., Cardoso, V. V., Flores, M. M., et al. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.10.012 · Cited by 6
Applications of Surface Plasmon Resonance in Human Health Care
Jahed, F. S., & Hamidi, S. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0170 · Cited by 6
The metaplastic effects of cordycepin in hippocampal CA1 area of rats
Mai, Z.-F., Cao, Z., Huang, S., Yan, W., Huang, J., Wu, B., & Li, C. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173946 · Cited by 6
Pannexin1 channels regulate mechanically stimulated but not spontaneous adenosine release
Lee, S. T., Chang, Y., & Venton, B. J. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04047-x · Cited by 6
Shalaby, H. N., Zaki, H. F., Ain-Shoka, A. A., & Mohammed, R. A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02977-2 · Cited by 6
Akköprü, H., Alnak, A., Karadoğan, Z. N., Çağlayan, A. O., Özçetin, M., & Coşkun, M. (2023) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2023.22509 · Cited by 6
Engineering G Protein-Coupled Receptors for Drug Design
Congreve, M., Dore, A. S., Jazayeri, A., & Nonoo, R. (2015) · NATO science for peace and security series. A, Chemistry and biology · doi:10.1007/978-94-017-9719-1_1 · Cited by 6
[Roles of adenosine receptors in Alzheimer's disease].
Yan, R., Hu, Z., Zhou, W., Wang, Q., & Zhang, Y. (2014) · PubMed · Cited by 6
Estradiol induces synaptic rearrangements
Grković, I., & Mitrović, N. (2020) · Vitamins and hormones · doi:10.1016/bs.vh.2020.04.006 · Cited by 6
Post-weaning social isolation impairs purinergic signaling in rat brain
Andrejew, R., Paim, M., Moritz, C. E. J., Carreño, F. O., Rates, S. M. K., Elisabetsky, E., Souza, D. O., Almeida, R. F., & Battastini, A. M. O. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105111 · Cited by 6
Urakubo, H., Yagishita, S., Kasai, H., Kubota, Y., & Ishii, S. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009364 · Cited by 6
Regulation of Cerebral Blood Flow: Response to Cytochrome P450 Lipid Metabolites
Harder, D. R., Rarick, K. R., Gebremedhin, D., & Cohen, S. S. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170025 · Cited by 7
Zou, Y., Nüsken, M., Liao, K., Hahn, K.-Y., Dasari, P., & Buhl, T. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.12.001 · Cited by 5
How to Maximize the Success of Stem Cell Autografts for Neuroregeneration
Chahine, N. A. (2015) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.1000271 · Cited by 5
Adžić, M., Laketa, D., Dragić, M., Lavrnja, I. C., & Nedeljković, N. (2023) · Glia · doi:10.1002/glia.24459 · Cited by 5
Aziz, N. A. W. A., Iezhitsa, I. N., Agarwal, R., Bakar, N. S., Latiff, A. A., & Ismail, N. M. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac047 · Cited by 5
Sobrevia (2013) · Global Journal of Pathology and Microbiology · doi:10.14205/2310-8703.2013.01.01.5 · Cited by 5
Adenosine Receptors and Alzheimer’s Disease
Blum, D. L., Sandau, U. S., Laurent, C., Batalha, V. L., Leboucher, A., Hamdane, M., Pasquier, F., Boison, D., Buée, L., & Lopes, L. V. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3903-5_19 · Cited by 6
Adenosine STEPs on synaptic function
Yasuda, R. P. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14901 · Cited by 5
Alves, M., Gerbatin, R. R., Kalmeijer, R., Fedele, D., Engel, T., & Boison, D. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110599 · Cited by 4
Liu, Y., Xiang, R., Lu, W., & Qin, X. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116845 · Cited by 4
Adenosine and Energy Metabolism—Relationship to Brain Bioenergetics
Chen, X., Hui, L., & Geiger, J. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3903-5_3 · Cited by 4
Adenosine exerts potent anticancer effects through diverse signaling pathways
Tsuchiya, A., Kanno, T., & Nishizaki, T. (2014) · Personalized Medicine Universe · doi:10.1016/j.pmu.2014.02.003 · Cited by 4
Yeung, P. K. F., Tinkel, J. L., & Seeto, D. (2016) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x15666151102102702 · Cited by 4
Adenosine and NMDA Receptors Modulate Neuroprotection-Induced NMDA Preconditioning in Mice
Ghislandi, A. B., Garcez, M. L., Zambon, G. M., Constantino, L. C., de Matos, D. N., Pescador, B., Tasca, C. I., & Boeck, C. R. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01463-0 · Cited by 4
Exogenous Adenosine Modulates Behaviors and Stress Response in Caenorhabditis elegans
da Silva, T. C., da Silveira, T. L., Venturini, L., Arantes, L. P., Martins, R. P., Soares, F. A. A., & Corte, C. L. D. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03727-5 · Cited by 5
Savio, L. E. B., Vuaden, F. C., Rosemberg, D. B., Bogo, M. R., Bonan, C. D., & Wyse, Â. T. D. S. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9321-y · Cited by 4
Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder
Petković, B. B., Kesić, S., & Pešić, V. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200115094642 · Cited by 4
Discovery of the first A 1 adenosine receptor ligand based on the chromone scaffold
Cagide, F., Reis, J., Gaspar, A., Chavarria, D., Kachler, S., Klotz, K., Gomes, L. R., Low, J. N., Vilar, S., Hripcsak, G. M., et al. (2016) · RSC Advances · doi:10.1039/c6ra02347a · Cited by 4
Grayson, B., Podda, G., Cilia, J., Woolley-Roberts, M., Neill, J. C., Fletcher, J., & Harte, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251381246 · Cited by 3
In silico exploration of cholinergic activity and neuroprotection of novel caffeine analogues
Obiol, D. J., Vietri, A., Munafó, J. P., Costabel, M. D., & Antollini, S. S. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151374 · Cited by 3
From Clinical to Basic Research: The Neuroprotective Effects and Mechanisms of Caffeine
Wang, L., & Wang, L. (2025) · Health and Metabolism · doi:10.53941/hm.2025.100008 · Cited by 5
Reconstruction of the adenosine system by bone marrow-derived mesenchymal stem cell transplantation.
Kang, H., Hu, Q. Z., Liu, X., Liu, Y., Xu, F., Li, X., & Zhu, S. (2012) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-5374.2012.04.002 · Cited by 3
Bernardi, A., Torres, O. V., Sosa, M. H., Muñiz, J. A., Urbano, F. J., Cadet, J. L., & Bisagno, V. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00200-5 · Cited by 3
[A Review of the State of Purinergic Signaling and Psychological Stress].
Ren, W., & Tang, Y. (2021) · PubMed Central · doi:10.12182/20210160102 · Cited by 3
Does dietary intake of caffeine have an effect on transient global amnesia?
Zeinalabedini, M., Mousavi, Z. S., Amjadi, A., Shapouri, M., Kavkani, B. A., Masoumvand, M., Mobarakeh, K. A., Gholamalizadeh, M., Valisoltani, N., Mohammadi, S., et al. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12408 · Cited by 3
da Costa, P., Schetinger, M. R. C., Baldissarelli, J., Reichert, K. P., Stefanello, N., Bottari, N. B., Vidal, T., da Cruz, I. B. M., Assmann, C. E., & Morsch, V. M. (2025) · Neurochemical Research · doi:10.1007/s11064-024-04327-1 · Cited by 4
Adenosine Receptors and Neuroinflammation
Ferrante, A., Simone, R. D., Ajmone‐Cat, M. A., Minghetti, L., & Popoli, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90808-3_9 · Cited by 3
Adenosine and Other Purinergic Products in Circadian Timing
Muheim, C., & Brown, S. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3903-5_11 · Cited by 4
Torfeh, A., Abdolmaleki, Z., Nazarian, S., & Beheshtiha, S. H. S. (2020) · The Anatomical Record · doi:10.1002/ar.24581 · Cited by 3
Goulart, V. G., Nazareth, Y. D. O., Latgé-Tovar, S., Rossetti, F. P., Maisonnette, S. S., Pandolfo, P., Landeira-Fernández, J., & Campello‐Costa, P. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115751 · Cited by 2
Xu, Q., Opoku, Y. N., Authi, K. S., & Cilibrizzi, A. (2025) · Cells · doi:10.3390/cells14151219 · Cited by 2
Noureen, B., Wang, M., Chen, Y., Ma, Y., Chen, W., Du, L., & Wu, C. (2025) · Talanta · doi:10.1016/j.talanta.2025.128759 · Cited by 2
Zhao, X., Deng, J., Xiong, Z., & Li, T. (2026) · Biomolecules · doi:10.3390/biom16030453 · Cited by 2
Caffeine, Adenosine A 1 Receptors, and Brain Cortex. Molecular Aspects
Cortés, A., Casadó-Anguera, V., Moreno, E., & Casadó, V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800634-4.00074-3 · Cited by 2
Contribution of neuroinflammation, resolution, and neuroprotection in neuropsychiatric diseases
Farooqui, A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88460-0.00002-3 · Cited by 2
Gleizes, M., Fonta, C., & Nowak, L. G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15558 · Cited by 2
Jiang, Q., Zhang, X., Lu, X., Li, Y., Lu, C., Chi, J., Ma, Y., Shi, X., Wang, L., & Li, S. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s427557 · Cited by 2
Neuroprotection induced by nucleosides
Piermartiri, T., & Tasca, C. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00064-6 · Cited by 2
Şener, N., Keti, D. B., Güleç, A., Canpolat, M., Per, H., Gümüş, H., & Muhtaroğlu, S. (2024) · Revista română de medicină de laborator · doi:10.2478/rrlm-2024-0021 · Cited by 2
Girish, B. S., Nikitha, B. S., Roopa, K., Meghana, C. S., & Srinivasan, R. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100197 · Cited by 3
Ketogenic Diet and Epilepsy: The Role of Adenosine
Rho, J. M., Zupec‐Kania, B., & Masino, S. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3903-5_27 · Cited by 2
The Role and Development of the Antagonist of Adenosine A2Ain Parkinson’s Disease
Aryati, W. D., Salamah, N. N., Syahdi, R. R., & Yanuar, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84272 · Cited by 2
Pedata, F., Pugliese, A. M., Corti, F., & Melani, A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3903-5_14 · Cited by 2
Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines
Moas-Héloire, V., Renault, N., Batalha, V. L., Arias, A. R., Marchivie, M., Yous, S., Deguine, N., Buée, L., Chavatte, P., Blum, D. L., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.030 · Cited by 2
Khairnar, A., Frau, L., Plumitallo, A., Morelli, M., & Simola, N. (2014) · Journal of Caffeine Research · doi:10.1089/jcr.2014.0006 · Cited by 2
Adenosine in the Neurobiology of Schizophrenia: Potential Adenosine Receptor-Based Pharmacotherapy
Ciruela, F., Fernández‐Dueñas, V., Contreras, F., Arnau, J. M., Menchón, J. M., Vallano, A., & Valle-León, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-17103-6_26 · Cited by 2
The Adenosine Receptor: A Homeostatic Neuromodulator for Fine-Tuning Control of Cognition
Chen, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-90808-3_15 · Cited by 2
Severe amnestic syndrome due to theophylline toxicity
Joyce, E., Olszewska, D. A., Davy, S. W., & Counihan, T. J. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-240273 · Cited by 2
Boussadia, Z., Chiodi, V., Pazienti, A., & Martire, A. (2022) · Purinergic Signalling · doi:10.1007/s11302-021-09835-1 · Cited by 2
Fiebrantz, A. K. B., Leite, L. F., Schwab, E. D. P., Bonini, J. S., & da Silva, W. C. F. N. (2023) · PubMed Central · doi:10.1101/lm.053785.123 · Cited by 2
Polyphenols and Neuroprotection: The Role of Adenosine Receptors
Sánchez-Melgar, A., Albasanz, J. L., & Martı́n, M. (2019) · Journal of Caffeine and Adenosine Research · doi:10.1089/caff.2019.0007 · Cited by 1
Contribution of neuroinflammation, resolution, and neuroprotection in neurotraumatic diseases
Farooqui, A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88460-0.00015-1 · Cited by 2
Dheer, A., Dixit, A. B., Tripathi, M., Chandra, P. S., & Banerjee, J. (2022) · Springer eBooks · doi:10.1007/978-981-16-8313-8_12 · Cited by 1
Mateus, J. M., Barateiro, A. P., Moreira, J. B., Santos, B., Płachtij, N., Sebastião, A. M., Fernandes, A., & Xapelli, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178381 · Cited by 1
Changes in the Expression of Purinergic Receptors of the CNS Cells During Cerebral Ischemia
Savinkova, I. G., Babkina, I., Morozova, M. P., & Горбачева, Л. Р. (2025) · Neurochemical Journal · doi:10.1134/s1819712425700667 · Cited by 1
Mihajlović, K., Dragić, M., Adžić, M., Martić, T., Stevanović, I. D., Vinit, S., Bleuzé, M., Mansart, A., Adam, L., & Nedeljković, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1778355 · Cited by 1
Deng, Y., He, Q., Yao, B., Chen, X., Cheng, G., Xu, M., Hu, J., Graça, L., Zhu, X., Zhang, X., et al. (2026) · Science Signaling · doi:10.1126/scisignal.aea4402 · Cited by 1
New Perspectives in Nuclear Neurology for the Evaluation of Parkinson's Disease
Benadiba, M., Luurtsema, G., Tumas, V., Buchpiguel, C. A., & Busatto, G. F. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130207 · Cited by 1
Bortolatto, C. F., Jessé, C. R., Wilhelm, E. A., & Nogueira, C. W. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00952.x · Cited by 1
Hypoxia Modulates the Adenosinergic Neural Network
Gaytan, S. P., & Pásaro, R. (2017) · InTech eBooks · doi:10.5772/65242 · Cited by 1
The Adenosine-Receptor Axis in Chronic Pain
Salvemini, D., Doyle, T. M., Largent‐Milnes, T. M., & Vanderah, T. W. (2018) · Springer eBooks · doi:10.1007/978-3-319-90808-3_16 · Cited by 1
Grković, I., Mitrović, N., & Dragić, M. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2021.11.005 · Cited by 1
Souza, J. R., Lima‐Silveira, L., Accorsi‐Mendonça, D., & Machado, B. H. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.11.010 · Cited by 1
Neuropharmacology of Alzheimer’s Disease and Dementia
Sattar, Y. (2018) · Journal of pharmacology & clinical research · doi:10.19080/jpcr.2018.06.555688 · Cited by 1
POTENTIAL OF ADENOSINE-SYSTEM-BASED THERAPIES IN THE TREATMENT OF NEUROIMMUNE DISORDERS
Peixoto, I. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/3cxd-am86 · Cited by 1
Mesial temporal lobe epilepsy: new emerging therapeutic approaches
Amaral, S. M. F. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/6rh3-s741 · Cited by 1
Application of Optical Nanoprobes for Supramolecular Biosensing
Das, R., Pal, R., Bej, S., Mondal, M., & Banerjee, P. (2023) · doi:10.1002/9781394167135.ch13 · Cited by 1
Transient Delivery of Adenosine as a Novel Therapy to Prevent Epileptogenesis
Boison, D., & Lusardi, T. A. (2015)
Adenosine A2A Receptor-Mediated Control of Non-Motor Functions in Parkinson’s Disease
Prediger, R. D., MATHEUS, F. C., de Oliveira, P. A., Rial, D., Moretti, M., Souza, A. C. G., Aguiar, A. S., & Cunha, R. A. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_10
Self-citationGomes, C. A., George, J., Chen, J., & Cunha, R. A. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_5
Self-citationMaia, A., & Soares, R. (2014)
Extracellular adenosine as a novel neuroimmune modulator
Chiu, G. S. (2014) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Purines and Neuronal Excitability: Links to the Ketogenic Diet [post-print]
Masino, S. A., Kawamura, M., Ruskin, D. N., Geiger, J. D., & Boison, D. (2012) · Trinity College Digital Repository (Trinity College, Hartford CT)
Walters, E. R. (2013) · Bradford Scholars (University of Bradford)
Siqueira, R. M. P. (2011) · Americanae (AECID Library)
Role of adenosine A2A receptor in controlling neuroinflammation mediated by retinal microglial cells
António, D., de la Rosa, F. J. C., & Ambrósio, G. (2011)
ELECTROCHEMICAL DETECTION OF ADENOSINE IN VIVO
Ross, A. E., & Venton, B. J. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814619776_0004
Ciruela, F., Fernández‐Dueñas, V., Altafaj, X., Contreras, F., Vallano, A., Menchón, J. M., & Valle-León, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-53126-7_29
Serchov, T., Atas, H. C., Normann, C., van Calker, D., & Biber, K. P. H. (2012)
Molecular Modelling and Simulations Applied to Challenging Drug Discovery Targets
Vivo, M. D., Masetti, M., & Rossetti, G. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781788010139-00317
Dechandt, C. R. P. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2018.tde-13092018-104230
Computer-Aided Design of Ligands at Multiple Protein Targets for Multifactorial Diseases
Kalash, L. N. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.38293
Adenosine and Adenosine A 2A Receptors as Targets for the Treatment of Niemann Pick Type C Disease
Ferrante, A., Visentin, S., Nuccio, C. D., Martire, A., & Popoli, P. (2019) · Journal of Caffeine and Adenosine Research · doi:10.1089/caff.2019.0014
The Yin and Yang of Adenosine Receptors: A Piquant Story
Köfalvi, A. (2020) · Journal of Caffeine and Adenosine Research · doi:10.1089/caff.2020.0004
Metadata
- Authors
- Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A.
- Affiliations
- University of Coimbra (PT)
- Corresponding author
- Cunha, Rodrigo A.
- Venue
- Biochimica et Biophysica Acta (BBA) - Biomembranes
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 1808
- Issue
- 5
- Pages
- 1380-1399
- ISSN
- 0005-2736 (ISSN-L)
- OpenAlex
- W2081196843
- Cited by
- 419
- References
- 473
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 15 · 2023: 21 · 2022: 30 · 2021: 24 · 2020: 37 · 2019: 43 · 2018: 36 · 2017: 30 · 2016: 27 · 2015: 38 · 2014: 32 · 2013: 22 · 2012: 26
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Biochimica et Biophysica Acta (BBA) - Biomembranes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundação para a Ciência e a Tecnologia
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- adenosine receptors, adenosine A1 receptor, adenosine A2A receptor, neuroprotection, neurodegeneration, neuromodulation, glutamatergic synapses, synaptic plasticity, ischemia, epilepsy, Parkinson's disease, Alzheimer's disease, neuroinflammation, neuron-glia communication, neurogenesis, growth factors, mental illness, adenosine receptor agonists
- MeSH terms
- Animals, Brain Diseases, Humans, Nerve Degeneration, Receptors, Purinergic P1, Neurotransmitter Agents, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review